Literature DB >> 1148385

The recognition and classification of immunodeficiency diseases with bacteriophage phiChi 174.

R J Wedgwood, H D Ochs, S D Davis.   

Abstract

A standard antigen to assess humoral responses is needed for the immunodeficiency syndromes. Bacteriophage phiChi 174 is the best available antigen. Large, standardized batches can be prepared, stored and distributed; samples for assay can be transported by mail. We have systematically studied the immune response to this antigen in over 200 persons, including 49 immunodeficiency patients. Phage provides consistent delineation of humoral responses in primary immunodeficiency diseases.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1148385

Source DB:  PubMed          Journal:  Birth Defects Orig Artic Ser        ISSN: 0547-6844


  13 in total

1.  Autoimmunity in the relatives of patients with immunodeficiency diseases.

Authors:  J M Friedman; P J Fialkow; S D Davis; H D Ochs; R J Wedgwood
Journal:  Clin Exp Immunol       Date:  1977-06       Impact factor: 4.330

Review 2.  Phage Therapy in the Era of Synthetic Biology.

Authors:  E Magda Barbu; Kyle C Cady; Bolyn Hubby
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-10-03       Impact factor: 10.005

3.  Antibody to bacteriophage phi X 174 synthesized by cultured human peripheral blood lymphocytes.

Authors:  J Bohnsack; H D Ochs; R J Wedgwood; S R Heller
Journal:  Clin Exp Immunol       Date:  1985-03       Impact factor: 4.330

Review 4.  Diagnosis of defects of antibody production.

Authors:  A M Ward
Journal:  J Clin Pathol Suppl (R Coll Pathol)       Date:  1979

5.  Variability in B cell maturation and differentiation in X-linked agammaglobulinemia.

Authors:  F E Leickley; R Buckley
Journal:  Clin Exp Immunol       Date:  1986-07       Impact factor: 4.330

6.  Adenosine deaminase and purine nucleoside phosphorylase deficiencies: evaluation of therapeutic interventions in eight patients.

Authors:  M L Markert; M S Hershfield; R I Schiff; R H Buckley
Journal:  J Clin Immunol       Date:  1987-09       Impact factor: 8.317

7.  Effect of rituximab on human in vivo antibody immune responses.

Authors:  Mark D Pescovitz; Troy R Torgerson; Hans D Ochs; Elizabeth Ocheltree; Paula McGee; Heidi Krause-Steinrauf; John M Lachin; Jennifer Canniff; Carla Greenbaum; Kevan C Herold; Jay S Skyler; Adriana Weinberg
Journal:  J Allergy Clin Immunol       Date:  2011-09-09       Impact factor: 10.793

8.  Rapid immune reconstitution of SCID-X1 canines after G-CSF/AMD3100 mobilization and in vivo gene therapy.

Authors:  Olivier Humbert; Frieda Chan; Yogendra S Rajawat; Troy R Torgerson; Christopher R Burtner; Nicholas W Hubbard; Daniel Humphrys; Zachary K Norgaard; Patricia O'Donnell; Jennifer E Adair; Grant D Trobridge; Andrew M Scharenberg; Peter J Felsburg; David J Rawlings; Hans-Peter Kiem
Journal:  Blood Adv       Date:  2018-05-08

9.  Antibody responses in vivo in chromosome instability syndromes with immunodeficiency.

Authors:  C M Weemaes; T H The; P J van Munster; J A Bakkeren
Journal:  Clin Exp Immunol       Date:  1984-09       Impact factor: 4.330

10.  Antibacterial efficacy of temperate phage-mediated inhibition of bacterial group motilities.

Authors:  In-Young Chung; Nuri Sim; You-Hee Cho
Journal:  Antimicrob Agents Chemother       Date:  2012-08-20       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.